New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma

J Natl Compr Canc Netw. 2018 May;16(5S):646-650. doi: 10.6004/jnccn.2018.0042.

Abstract

The NCCN Guidelines Panel for Melanoma debuted new guidelines for uveal melanoma at the NCCN 23rd Annual Conference. Although uveal melanoma and cutaneous melanoma share the same name, they do have different characteristics and treatments. The NCCN Guidelines describe how tumor size guides therapeutic options, which for most tumors is radiotherapy. Predictors of melanoma-related mortality include advanced age, larger tumor size, and histopathologic and molecular features. The NCCN Guidelines for Cutaneous Melanoma have not changed notably, but adjuvant therapy with immunotherapies is now recommended. The best second-line treatment in the metastatic setting remains unclear.

Trial registration: ClinicalTrials.gov NCT02224781.

Publication types

  • Practice Guideline

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / antagonists & inhibitors
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / immunology
  • Brachytherapy / methods
  • Brachytherapy / standards
  • Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors
  • Costimulatory and Inhibitory T-Cell Receptors / genetics
  • Costimulatory and Inhibitory T-Cell Receptors / immunology
  • Disease Progression
  • Disease-Free Survival
  • Eye Enucleation / methods
  • Eye Enucleation / standards
  • Liver Neoplasms / genetics
  • Liver Neoplasms / immunology
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy*
  • Lymphatic Metastasis / pathology
  • Lymphatic Metastasis / radiotherapy
  • Medical Oncology / standards
  • Melanoma / genetics
  • Melanoma / immunology
  • Melanoma / pathology
  • Melanoma / therapy*
  • Neoadjuvant Therapy / methods
  • Neoadjuvant Therapy / standards
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasm Staging
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics
  • Randomized Controlled Trials as Topic
  • Skin Neoplasms / genetics
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*
  • Societies, Medical / standards*
  • United States
  • Uveal Neoplasms / genetics
  • Uveal Neoplasms / immunology
  • Uveal Neoplasms / pathology
  • Uveal Neoplasms / therapy*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Costimulatory and Inhibitory T-Cell Receptors
  • Protein Kinase Inhibitors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf

Supplementary concepts

  • Uveal melanoma

Associated data

  • ClinicalTrials.gov/NCT02224781